Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

AstraZeneca UK Limited
Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU
Telephone: +44 (0)1582 836 000
Fax: +44 (0)1582 838 000
Medical Information Direct Line: +44 (0)1582 836 836
Medical Information e-mail: medical.informationuk@astrazeneca.com
Customer Care direct line: +44 (0)1582 837 837
Medical Information Fax: +44 (0)1582 838 003

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 30/04/2012
PIL Naropin 2 mg/ml Solution for Infusion and 2mg/ml, 7.5 mg/ml, 10 mg/ml Solution for Injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 30/04/2012 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to storage instructions
  • Change to side-effects
Updated on 21/11/2008 and displayed until 30/04/2012
Reasons for adding or updating:
  • Joint PIL superseded by PILs for individual presentations
  • Change to warnings or special precautions for use
Updated on 16/10/2008 and displayed until 21/11/2008
Reasons for adding or updating:
  • Individual presentations superseded by joint PIL
Updated on 24/04/2007 and displayed until 16/10/2008
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
Updated on 29/07/2004 and displayed until 24/04/2007
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Active Ingredients/Generics

 
  ropivacaine hydrochloride